These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection. Lee NR; Jang JW; Kim HS; Yhim HY Korean J Intern Med; 2015 Jul; 30(4):550-3. PubMed ID: 26161025 [No Abstract] [Full Text] [Related]
29. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer. Berchem G; Dewilde S; Mahassen P Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172 [TBL] [Abstract][Full Text] [Related]
30. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Deslandres M; Sibaud V; Chevreau C; Delord JP Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113 [TBL] [Abstract][Full Text] [Related]
31. RASopathic alopecia: hair changes associated with vemurafenib therapy. Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419 [No Abstract] [Full Text] [Related]
32. Should vascular effects of newer treatments be addressed more completely? Yang EH; Watson KE; Herrmann J Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824 [No Abstract] [Full Text] [Related]
33. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia. Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743 [No Abstract] [Full Text] [Related]
34. Chemotherapeutic agents and the skin: An update. Heidary N; Naik H; Burgin S J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708 [TBL] [Abstract][Full Text] [Related]
35. Painful pustular eruption in the groin and the scrotum induced by erlotinib. Cholongitas E; Kokolakis GP; Ioannidou D J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):507-8. PubMed ID: 18363921 [No Abstract] [Full Text] [Related]
36. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484 [No Abstract] [Full Text] [Related]
37. Severe epistaxis with tyrosine kinase inhibitors. Hall PS; Kancherla K; Sastry PS; Brown JE Clin Oncol (R Coll Radiol); 2008 May; 20(4):318-9. PubMed ID: 18353621 [No Abstract] [Full Text] [Related]
38. Cardiovascular toxicity of new agents. Maitland ML Clin Adv Hematol Oncol; 2008 Sep; 6(9):657-9. PubMed ID: 18827788 [No Abstract] [Full Text] [Related]
39. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Winn SK; Ellis S; Savage P; Sampson S; Marsh JE Nephrol Dial Transplant; 2009 Feb; 24(2):673-5. PubMed ID: 19039026 [TBL] [Abstract][Full Text] [Related]
40. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings]. Pérez López G; Carrasco De La Fuente M; Menacho Román M; González Albarrán O; Cano Megías M Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]